Role of Specific microRNAs in Cluster Headache
Launched by IRCCS NATIONAL NEUROLOGICAL INSTITUTE "C. MONDINO" FOUNDATION · Jul 9, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the role of specific microRNAs (small molecules that help regulate gene expression) in cluster headaches, a severe type of headache that can occur in episodes. Researchers want to understand how these microRNAs, along with certain neuropeptides (substances that can trigger headache attacks), are involved in causing cluster headaches. They will be looking at blood samples from people with chronic and episodic cluster headaches, as well as healthy individuals, to see if there are any differences in the levels of these molecules.
To participate in this study, you must be between 18 and 65 years old and meet specific criteria based on your headache type. For example, individuals with episodic cluster headaches should have been diagnosed with this condition for at least a year. Participants can expect to provide blood samples and may be asked questions about their health. This study is important because it aims to shed light on the biological factors that contribute to cluster headaches, which could lead to better treatments in the future.
Gender
ALL
Eligibility criteria
- • - Healthy Controls
- Inclusion Criteria:
- • age between \>18 and \<65 years
- Exclusion Criteria:
- • diagnosis of primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension type headache is allowed)
- • diagnosis of neurological disorders
- • diagnosis of medical conditions considered clinically relevant by the researcher
- • pregnant and lactating women
- • taking NSAIDs, triptans or opiates in the previous 24 hours
- • Episodic Cluster Headache
- Inclusion Criteria:
- • diagnosis of Episodic Cluster Headache according to ICHD-III criteria (at least 1 year at screening)
- • age between \>18 and \<65 years of both genders
- Exclusion Criteria:
- • concomitant diagnosis of other primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed)
- • diagnosis of other neurological disorders
- • diagnosis of medical conditions considered clinically relevant by the researcher
- • diagnosis of chronic pain syndrome of any nature
- • pregnant and lactating women
- • use of substances of abuse
- • Chronic Cluster Headache
- Inclusion Criteria:
- • diagnosis of Chronic Cluster Headache according to ICHD-III criteria (at least 1 year at screening)
- • age between \>18 and \<65 years of both genders
- Exclusion Criteria:
- • concomitant diagnosis of other primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed)
- • diagnosis of other neurological disorders
- • diagnosis of medical conditions considered clinically relevant by the researcher
- • diagnosis of chronic pain syndrome of any nature
- • pregnant and lactating women
- • use of substances of abuse
About Irccs National Neurological Institute "C. Mondino" Foundation
The IRCCS National Neurological Institute "C. Mondino" Foundation is a prominent research institution in Italy dedicated to advancing the field of neurology through innovative clinical trials and scientific research. As a recognized IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), the foundation focuses on the diagnosis, treatment, and rehabilitation of neurological disorders, fostering collaboration among healthcare professionals, researchers, and academic institutions. Committed to translating cutting-edge research into clinical practice, the foundation aims to enhance patient care and improve outcomes for individuals affected by neurological diseases. Its rigorous approach to clinical trials ensures the highest standards of scientific integrity and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported